Enhanced Genomics is the only biotechnology company able to define causal biology from disease-associated variants on a genome-wide scale, enabling the rapid identification of new, high-confidence, first-in-class therapeutic targets for common diseases, with blockbuster potential.
Unlocking decades worth of genetic data and providing unparalleled validation via its proprietary 3D multi-omics platform and data-rich human cell type-specific atlas, the Company is able to expedite drug discovery and precision medicine.
Enhanced’s 3D multi-omics platform is the only genome-wide, hypothesis-free technology able to translate massive amounts of disease-associated variant data into causal biology on a cell-type-specific basis. This approach supports both target prioritization, more than doubling the probability of success, and target identification, vastly increasing the number of novel disease targets that can be identified, more efficiently and in a fraction of the time previously possible. It also allows the stratification of patients into responder groups to improve and accelerate clinical trials.
Enhanced Genomics has an active in-house target discovery and development program, focusing on common diseases with large unmet needs. The Company also welcomes enquiries from potential partners looking to enable and accelerate their discovery and development initiatives.